Beijing, Nov 3 A home-grown drug treating Alzheimer’s disease,received the China’s regulator approval for the market launch and to be used for the treatment of “mild to moderate Alzheimer’s disease and improving cognitive function.” Alzheimer’s disease is a progressive brain disorder that impairs memory, affecting the ability of patients to carry out simple tasks.
The new drug, Oligomannate (GV-971), is the first to be approved for Alzheimer’s disease globally since 2003, said Green Valley Pharmaceutical Co., which developed the drug along with Ocean University of China, Shanghai Institute of Materia Medica under Chinese Academy of Sciences.
The oral drug, GV-971, is the only one out of more than 320 developed by pharmaceutical companies around the globe that succeeded after clinical trials.
A multi-centre global phase 3 clinical trial with sites in the US, Europe and Asia is planned to be initiated in early 2020 to support global regulatory filing of Oligomannate.
An effective treatment for Alzheimer’s that affects about 48 million people in the world could easily become a big hit globally.
Results of the 36-week-long study showed that Oligomannate can improve cognitive function in mild-to-moderate Alzheimer’s disease patients as early as week 4 and the benefit was sustained at each follow-up assessment visit.